IP survey in Western Switzerland, the booming of the life sciences sector?

Switzerland has become an attractive place that is highly active in the life sciences and in particular in hosting biotech companies. by Emmanuel Jelsch , 07/01/2009

Review on The Biofuel Market

The biofuel market is estimated at 33 billion Euros with a double digit annual growth. by Philippe Tramoy , 03/12/2008

Tissue engineering: Strengthening industry competitiveness while reducing animal testing

The goal of tissue engineering is to recreate the whole or part of human tissues in vitro. The industry of tissue engineering is still in its infancy and many of the tissue-engineered products are still at development stages. But it is now a fast growing industry.02/12/2008

Major Pharma's takeovers of the week

Despite the grim financial period, blue chip pharmaceutical companies are buying their younger siblings and consolidating their pipeline in specialized drug areas or acquiring new technologies and therapeutic domains.27/11/2008

Device and Drug Combination Products: a New Regulatory, Reimbursement and Marketing Challenge

More and more drug-device combination products have appeared on the market, incorporating cutting edge technologies from nanotechnology, drug-delivery and gene therapy systems.03/11/2008

Pricing and Reimbursement challenges for New Pharmaceuticals and Medical Devices

Adaptation to the new rules of the pricing and reimbursement is a major challenge for the pharmaceutical and medical devices companies. 29/09/2008

Excellent financing opportunity for life sciences companies

The practice of raising large amounts of money in Switzerland shows that Swiss and foreign companies appreciate the outstanding market environment in Switzerland and at SWX. 01/07/2008

Advanced Miniature Diaphragm Pumps and Solenoid Valves Drive Portable Medical Devices

Medical therapies are being driven to reduce hospital costs by administering treatments at home or even on the go. This demand has launched new generations of portable devices. 18/06/2008

White biotechnology: the invisible revolution…

The life science market is generally segmented in four segments: Biotechnology, Pharmaceuticals, Diagnostics and Medical Devices. A common problem is the confusion between the biotechnology and pharmaceutical segments. 22/02/2008


Headlines




Partnerships
August 11th, 2010, Alectos Therapeutics announced a research collaboration with Merck to identify and develop compounds that modulate O-linked N-acetylglucosaminidase (O-GlcNAcase) an enzyme that is believed to be involved in the development of Alzheimer's disease and potentially other disorders. The agreement provides Merck with a worldwide, exclusive license to research, develop and commercialize compounds that modulate this target.
July 27th, 2010, Merck, known outside the U.S. and Canada as MSD, and Sinopharm announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting and marketing Merck's pharmaceutical products in China.
June 17th, 2010, Neurocrine Biosciences announced that they had established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR-119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR-119 agonist products.